LifeCell - 500 Beiträge pro Seite

[Dennie]

Warum steigt die Aktie in Deutschland wo sie doch in USA 10% verlohren hat Danke

[HundVincent]

Salut Dennis

Der Verlust in den USA war nach- bzw. außerbörslich, wahrscheinlich verursacht durch den sukzessiven Ausstieg eines LIFC haltenden Fonds.
Den Kursprung heute in Deutschland verursacht ein gestriger Bericht im US-Fernsehen über Lifecell, der von vielen als so positiv erachtet wird, daß sie kaufen. (Dessen Ankündigung war wohl auch der Grund für die bis Börsenschluss sehr freundliche Tendenz von LIFC an der Nasdaq).

Ein Kauf kann m. E. nicht schaden, ich wäre aber vorsichtig mit der erheblichen Tages-Volatilität der Aktie hier in Deutschland.

Gruß

[HundVincent]

sorry, DenniE: s = e

[Dennie]

Danke

[wombat2000]

wieder ein kleiner fortschritt:

Thursday April 18, 7:07 am Eastern Time
Press Release
SOURCE: LifeCell Corporation
LifeCell Corporation Signs Agreement with Wright Medical Group To Develop a New Orthopedic Product
BRANCHBURG, N.J., April 18 /PRNewswire-FirstCall/ -- LifeCell Corporation (Nasdaq: LIFC - news), a leader in the development and commercialization of biologically based solutions to repair or replace the body`s damaged tissue, announced today that it has entered into an exclusive agreement with Wright Medical Group, Inc., to develop and supply a product based on LifeCell`s proprietary acellular tissue matrix technology for use in orthopedic surgery. Wright Medical Group, a global orthopedic medical device company, will market the product in conjunction with its comprehensive bio-orthopedic portfolio of products.

``LifeCell intends to commercialize several orthopedic products in the future. We are pleased to develop this product with Wright Medical, one of the most successful company`s in the orthopedic industry. With Wright Medical`s long history in the orthopedic markets and its strong relationships with orthopedic surgeons, we believe that this agreement will deliver attractive results for both companies,`` said Paul Thomas, President and CEO of LifeCell. ``Additionally, the agreement confirms the versatility of our proprietary acellular tissue matrix for potential use in a broad array of surgical applications and should enable us to leverage our core technology beyond our current products and markets.``

About LifeCell Corporation

LifeCell is a leader in developing and marketing biologically based solutions for the repair and replacement of damaged or inadequate tissue in numerous different clinical applications. The Company`s proprietary tissue matrix technology removes cells from allograft tissue and preserves the tissue without damaging the essential biochemical and structural components necessary for normal tissue regeneration. LifeCell currently markets three proprietary human tissue based products: AlloDerm® for plastic reconstructive and burn procedures through LifeCell`s direct sales force and for periodontal procedures through BioHorizons, Inc.; Cymetra(TM), a version of AlloDerm in particulate form for the correction of soft tissue defects, through LifeCell`s direct sales force and a co-promotion agreement with OMP, Inc.; and Repliform(TM), a version of AlloDerm for urology and gynecology procedures, through a marketing and distribution agreement with Boston Scientific Corporation. The Company`s development programs include the application of its tissue matrix technology to vascular, nerve and orthopedic tissue repair; investigation of human tissues as carriers for therapeutics; Thrombosol(TM), a formulation for extended storage of platelets and technologies to enhance the storage of red blood cells for transfusion. Visit our website at http://www.lifecell.com.

This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, such as our expectation for product development and entry into target markets. Forward-looking statements represent management`s judgment regarding future events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements due to a number of factors. These factors include the risks detailed in LifeCell`s Annual Report on Form 10-K for the year ended December 31, 2001 and other reports filed with the Securities and Exchange Commission.

SOURCE: LifeCell Corporation

einsammeln, solange sie noch preiswert sind
viel erfolg

[kiju]

Diese Entwicklung ist mir unklar; ?

[bagg]

@ all,
hat keiner mehr lifecellaktien.
überlege ob ich wieder reingehe.
oder wie seht ihr das?

mfg bagg